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EDITORIAL
Atrial fibrillation (AF) is a global challenge, with an estimated 
prevalence of 1 - 2% in the general population.[1] The prevalence 
increases with age,[1] and AF affects up to 15% of octogenarians. AF is 
independently associated with mortality, cardiac failure and non-fatal 
stroke.[1,2] Thromboprophylaxis for high-risk patients is provided 
with oral anticoagulation (OAC) using vitamin K antagonists 
(VKAs), such as warfarin. Meta-analysis of 5 randomised clinical 
trials demonstrated that OAC results in a relative risk reduction of 
68% for ischaemic stroke.[3] Over the past decade, the use of novel 
oral anticoagulants (NOACs) has gained traction, with randomised 
trials showing non-inferiority of these drugs for the prevention of 
ischaemic stroke compared with VKAs, as well as a lower risk of 
cerebrovascular haemorrhage. VKAs or NOACs, however, are best 
avoided in patients who are intolerant to their effects (e.g. life-
threatening haemorrhage), non-adherent or have an unacceptably 
high bleeding risk.
Percutaneous left atrial appendage occlusion (LAAO) is an 
alternative approach to thromboprophylaxis in AF, predicated on the 
fact that <10% of clinical emboli in non-valvular AF originate outside 
the LAA.[4] The LAA is excluded as an embolic source by placement 
of an occluder device into the ostium of the LAA via the femoral vein 
and interatrial, transseptal puncture. 
The Watchman Left Atrial Appendage System for Embolic 
Protection in Patients With Atrial Fibrillation (PROTECT AF)[5] 
trial prospectively randomised 707 patients with non-valvular AF 
to LAAO or warfarin. After 2 years of follow-up, the cumulative 
adverse event rate (stroke, cardiovascular/unexplained death or 
systemic embolism) was 5.9% for the LAAO arm, compared with 8.3% 
for the warfarin group, indicating non-inferiority. Although the 
Prospective Randomized Evaluation of the LAA Closure Device in 
Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy 
(PREVAIL)[6] trial (mimicking the original PROTECT AF protocol) 
failed to demonstrate non-inferiority of LAAO compared with 
warfarin, a significantly lower adverse event rate was recorded for 
LAAO.[6,7] More recently, the Left Atrial Appendage Closure vs. Novel 
Anticoagulation Agents in Atrial Fibrillation (PRAGUE-17) study[8] 
performed a head-to-head comparison between NOACs and LAAO, 
showing non-inferiority (p=0.004).[9] Procedural success rates are 
high and complication rates low with modern devices: the Amulet 
LAAO device (Abbot Vascular, St Paul, MN, USA) has demonstrated 
99% implantation success,[10,11] with only a 0.2% stroke and 0.9% major 
vascular complication rate. In a large, pooled study of 5‐year 
PROTECT AF and PREVAIL trial data performed in 2019, LAAO 
was not only cost‐effective, but even demonstrated a cost advantage 
compared with warfarin and NOACs.[7]
While VKAs remain the mainstay of thromboprophylaxis in 
South Africa (SA), many AF patients are receiving suboptimal 
protection with OAC due to non-adherence, contraindications and 
complications.[12] In the Atrial fibrillation Clopidogrel Trial with 
Irbesartan for prevention of Vascular Events (ACTIVE W), SA 
participants demonstrated international normalised ratios (INRs) 
in the therapeutic range only 40% of the time.[13] Clarkesmith et al.[14] 
performed a systematic review in 2017 regarding interventions 
for OAC compliance in AF and found that there is insufficient 
evidence to draw definitive conclusions regarding the impact of 
educational or behavioural interventions. Very limited local data exist 
on percutaneous LAAO, with a single case series published in 2013.[15] This 
procedure, however, is an attractive alternative to OAC, but is currently 
performed only in a few centres in SA. LAAO should be considered 
by referring clinicians as an alternative to OAC in patients who are 
intolerant, non-adherent or who have a high bleeding risk.
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